Multiple Sclerosis Journal · 2021 · 30 citations · 5 references
PharmacyNeurologyPharmacotherapyMonoclonal AntibodiesNeuroimmunologyRheumatologyMonoclonal Antibody TherapyMultiple SclerosisMultiple Sclerosis PharmacotherapyTherapeutic Monoclonal AntibodiesAnti-cd20 Antibody TherapyAnti-cd20 TherapyMultiple Sclerosis TherapyPlacebo-controlled Efficacy AssessmentPrimary Outcome AnalysisRelapsing-remitting Multiple Sclerosis TreatmentT1 DiseaseT2* Imaging
BACKGROUND: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, has been developed as a treatment for relapsing multiple sclerosis (RMS) which can be self-administered at home. OBJECTIVE: To investigate the efficacy and safety of ofatumumab in RMS patients from Japan and Russia. METHODS: APOLITOS included a 24-week, double-blind, placebo-controlled core-part followed by an open-label extension-part. Patients were randomized (2:1) to subcutaneous ofatumumab 20 mg or placebo. Primary outcome was the number of gadolinium-enhancing (Gd+) T1 lesions per scan over 24 weeks. RESULTS: < 0.001) and the results were consistent across regions (Japan/Russia). Ofatumumab reduced annualized T2 lesion and relapse rate versus placebo by week 24. Both groups showed benefit from ofatumumab in the extension-part. Incidence of adverse events was lower with ofatumumab versus placebo (69.8% vs 81.0%); injection-related reactions were most common. No deaths, opportunistic infections, or malignancies were reported. CONCLUSION: Ofatumumab demonstrated superior efficacy versus placebo, with sustained effect through 48 weeks in RMS patients from Japan/Russia. Switching to ofatumumab after 24 weeks led to rapid radiological and clinical benefits. Safety findings were consistent with pivotal trials.
5
Rating neurologic impairment in multiple sclerosis
John F. Kurtzke · Neurology · 1983 · 14.9K citations
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman, Stephen C. Reingold, Brenda Banwell et al. · Annals of Neurology · 2011 · 9.8K citations · Full text
Medicine, Neurology, Neuroscience +10
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser, Amit Bar‐Or, Jeffrey Cohen et al. · New England Journal of Medicine · 2020 · 700 citations · Full text
Christian Klein, Alfred Lammens, Wolfgang Schäfer et al. · mAbs · 2013 · 386 citations · Full text
Pharmacy, Immunology, Oncology +17